Microbiome-Targeted Antibiotics Provide No Additional Microbiologic or Inflammatory Benefit during Cystic Fibrosis Pulmonary Exacerbations: Results from the CFMATTERS Trial
Gisli G Einarsson, Andrew J Lee, Zina Alfahl, Lauren Kerrigan, Joseph A Eustace, Sinéad Weldon, Barry J Plant, J Stuart Elborn, Clifford C Taggart, Marcus
Authors
- S Weldon
- Barry J. Plant (ORCID: https://orcid.org/0000-0002-4611-6768)
- Clifford C. Taggart (ORCID: https://orcid.org/0000-0002-9930-2978)
- Zina Alfahl (ORCID: https://orcid.org/0000-0002-9557-1732)
- A Lee
- Michael M. Tunney (ORCID: https://orcid.org/0000-0002-7433-7074)
- Joseph A. Eustace
- G.G. Einarsson (ORCID: https://orcid.org/0000-0003-1353-950X)
- M A Mall
- J Stuart Elborn
- Lauren Kerrigan
Institutions
- Queen's University Belfast (GB)
- University College Cork (IE)
- Cork University Hospital (IE)
- German Centre for Cardiovascular Research (DE)
- Charité - Universitätsmedizin Berlin (DE)
Publication Details
- Journal
- American Journal of Respiratory and Critical Care Medicine
- Published
- 2026-06-29
- DOI
- https://doi.org/10.1093/ajrccm/aamag336
- Primary Topic
- Cystic Fibrosis Research Advances
- Type
- article
- Field-Weighted Citation Impact
- 0.00